Unisphere Establishment Increases Position in Boston Scientific Co. (NYSE:BSX)

Unisphere Establishment raised its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 10.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,391,400 shares of the medical equipment provider's stock after acquiring an additional 225,000 shares during the period. Boston Scientific makes up about 1.9% of Unisphere Establishment's investment portfolio, making the stock its 15th largest position. Unisphere Establishment owned 0.16% of Boston Scientific worth $213,600,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. TFC Financial Management Inc. raised its holdings in shares of Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. Global Wealth Strategies & Associates raised its stake in Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC purchased a new stake in Boston Scientific during the fourth quarter worth $29,000. Valley National Advisers Inc. boosted its position in Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 286 shares in the last quarter. Finally, Fairway Wealth LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $36,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Friday, January 10th. Argus set a $130.00 price target on Boston Scientific in a report on Tuesday, February 18th. Needham & Company LLC upped their target price on Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Finally, Truist Financial lifted their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Twenty-three investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $114.52.

Insider Buying and Selling

In other news, CFO Daniel J. Brennan sold 15,087 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the sale, the chief financial officer now owns 241,451 shares of the company's stock, valued at $25,369,256.57. This represents a 5.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the transaction, the executive vice president now owns 25,443 shares in the company, valued at $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 138,009 shares of company stock worth $14,407,381. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

NYSE BSX traded up $1.75 during mid-day trading on Friday, hitting $104.94. The stock had a trading volume of 7,363,218 shares, compared to its average volume of 6,346,832. Boston Scientific Co. has a twelve month low of $71.82 and a twelve month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The firm's 50 day moving average is $98.59 and its 200 day moving average is $95.37. The stock has a market capitalization of $155.21 billion, a price-to-earnings ratio of 83.95, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 earnings per share. Equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.